Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial

Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial

Abstract Background The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I). Herein, we aimed to establish a robust method for the manufacturing...

Full description

Bibliographic Details
Main Authors: Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, Noriyuki Tomiyama, Tadashi Watabe
Format: Article
Language:English
Published: SpringerOpen 2024-04-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Targeted alpha therapy
Astatine
[211At]NaAt
Automated dry distillation system
Thyroid cancer
Online Access:https://doi.org/10.1186/s41181-024-00257-z

Internet

https://doi.org/10.1186/s41181-024-00257-z

Similar Items